



**Health and
Disability Ethics
Committees**

**Northern A Health and Disability
Ethics Committee**

**Annual Report
2022**

This document is available on the New Zealand Health and Disability Ethics Committee website: www.ethics.health.govt.nz



This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share i.e., copy and redistribute the material in any medium or format; adapt i.e., remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made.

Contents

About this report	1
About the committee.....	1
Chairperson’s report.....	2
Applications reviewed	3
Complaints and overdue application summary.....	4
Complaints received.....	4
Overdue review	4
Appendix 1: Details of applications reviewed.....	5
Applications reviewed by full committee	5

About this report

This report is a summary of the activities of the Northern A Health and Disability Ethics Committees (HDEC) for the period of 01 July 2021 – 30 June 2022. It includes a summary of the applications reviewed during the year, details of any complaints received (and how they were resolved), and a list of new applications submitted. Previous HDEC annual reports included information on committee membership and attendance. These details are no longer included in the report.

About the committee

The Northern A Health and Disability Ethics Committees (HDEC) is a Ministerial committee established under section 87 of the [Pae Ora \(Healthy Futures\) Act 2022](#). Its members are appointed by the Minister of Health through the public appointments process.

The primary function of the Committee is to provide independent ethical review of health research and innovative practice in order to safeguard the rights, health and wellbeing of consumers and research participants and, in particular, those persons with diminished autonomy by checking that it meets or exceeds established [ethical standards](#).

Approvals and registrations

The Northern A HDEC is approved by the Health Research Council Ethics Committee for the purposes of section 25(1)(c) of the [Health Research Council Act 1990](#).

The Northern A HDEC is registered (number IRB00008714) with the United States' [Office for Human Research Protections](#). This registration enables the committee to review research conducted or supported by the US Department of Health and Human Services.

Chairperson's report

As the Chair of Northern A HDEC for the past year, I am pleased to present this Annual Report summarising the work of the Committee. In the year ending June 2022, the committee reviewed a total of 91 applications. 88 applications were reviewed at full committee meetings, while 3 were reviewed through the expedited (low risk) pathway. Two members of the Committee also sat on the COVID-19 Emergency Committee.

Northern A has been fortunate to enjoy full membership and excellent attendance over the reporting period. Northern A has functioned in accordance with the HRCEC's expectations for proper process and membership, the Guidelines for the Approval of Ethics Committees, and HDECs Standard Operating Procedures.

All Northern A meetings are held by Zoom, with applicants who choose to do so attending at a pre-arranged time. Attendance by applicants is the norm and is always of assistance to the Committee and to be encouraged. Meeting remotely brings some challenges but has generally worked well and is no doubt simpler for applicants. It also allows representatives of an international commercial Sponsor to join the meeting, which occurs relatively frequently. However, the importance of ensuring that there are face to face gatherings for training and team building purposes has been highlighted by the absence of such opportunities throughout the COVID-19 pandemic, and by the commitment to remote meetings. I would strongly encourage priority being given to in-person opportunities in the near future, particularly with many recent appointments across the committees. I also note the importance of regular meetings of the Chairs (remotely) which has recently occurred on a monthly basis, and I encourage the continuation of this.

The recent appointments to Northern A are excellent and add important expertise and enhance the diversity of members. The members work well together to thoroughly review applications in accordance with the NEAC Standards (2019). The ERM platform is now well established and has provided an improved experience for committee members in terms of the ability to access applications and relevant historical information, as well as the key task of inputting reviews. The Secretariat has been responsive to requests for modifications to ERM to make the platform increasingly user-friendly. The Secretariat continues to work on updating materials relevant to the application process in consultation with Committee Chairs, some examples being in relation to advertising and engaging more fully with disability in research.

There are areas of research which I anticipate will become increasingly significant and important to monitor, including genetic research, the use of AI, commercial relationships between researchers and other practitioners and the ever-present complexities of research on those who cannot consent. The committee strives to address these within the NEAC Standards but the importance of those Standards being a living document, reflecting regular change and the importance of clear legislative guidance (currently lacking) is noted.

I express my gratitude to all members and staff of the HDEC Secretariat for their hard work and support of me in my capacity as Chair, and I acknowledge the generosity of members across the HDEC committees who when required, are co-opted to assist. It is my pleasure to serve as the Chair of Northern A and I look forward to the coming year.

Catherine Garvey

Chair – Northern A HDEC

Applications reviewed

Summary of applications received by full EC

The Secretariat notes that HDEC cannot defer, however they can provisionally approve. We have answered as if defer is a provisional approval.

No. of applications approved	1
No. of applications approved subject to conditions (minor, non-standard conditions)	21
No. of applications deferred and subsequently approved (provisionally approved before approval)	43
No. of applications deferred as at time of report (provisionally approved)	3
No. of applications that were declined because of no/insufficient consultation with appropriate Māori/whanau/iwi/hapu	1
No. of applications that were declined because of no/insufficient consultation with appropriate cultural group	0
No. of applications declined (this <u>excludes</u> those with no/insufficient consultation with appropriate Māori/whanau/iwi/hapu/cultural group)	16
No. of applications which were invalidated for incompleteness	0
<i>No. of applications which do not require ethics committee approval (applications submitted to all Committees that were out of scope (total across Committees)) Note: this number is greatly increased from prior reports due to the new Ethics Review Manager automatic scope check process</i>	382
No. of studies withdrawn by researcher (none made to meetings or reviewed)	1
No. of studies terminated by sponsor	0
No. of studies transferred to another EC	0
Total number of applications received by full EC	86

Summary of applications received under expedited / low risk review

No. of applications approved	0
No. of applications approved subject to conditions	1
No. of applications deferred and subsequently approved	1
No. of applications deferred as at time of report	0
No. of applications which do not require ethics committee approval (applications submitted to Committee that were incomplete or out of scope)	1
<i>No. of applications referred for full committee review</i>	4
No. of applications declined	0
No. of studies withdrawn by researcher	0
Total number of applications received under expedited / low risk review	3

Total number of applications received:

89

Complaints and overdue application summary

This section outlines complaints about decisions made by the Committee during 2022.

Complaints received

Complaint one

Type of complaint: Privacy breach

Review date: Resolved 22 March 2022

Complaint received: 11 March 2022

Nature of complaint:

The Secretariat were copied in an email to a principal investigator from someone who had been sent a letter with the full name and date of birth of both a woman and her child to someone with a similar name but was not the correct recipient. The recipient notified the investigator and HDEC of the error.

Actions taken:

The investigator quickly responded and apologised for the error. They explained that due to the limitations of the records they were using that were from around 50 years ago, they had to use a wide range of approaches to match records and searched for the most recent contact. In this case, the match of the name was correct but incomplete and the recipient was contacted in error.

After discussion with the Chair, the investigator was advised to log the data breach as a protocol violation.

Outcome:

In the study's progress report, an update and overview of the study error was submitted and subsequently reviewed and approved by the Committee, who agreed that appropriate action had been taken in response to this error. The investigator noted this was the only instance that this occurred, and that an apology would be offered to the correct recipient if they manage to contact them.

Overdue review

Average review times consider the time taken for the Secretariat to process applications and the time taken for the Committee to review applications. The clock is stopped when a decision letter is emailed to applicants. Average review times exclude time taken for researchers to respond to requests for further information. Researchers have up to 90 days to respond.

Average review time was 39 days for expedited applications. Target timeframe for expedited applications is 15 calendar days. ([Standard Operating Procedures for Health and Disability Ethics Committees](#), para 9-102).

Average review time was 46 days for full applications. Target timeframe for full applications is 35 days. ([Standard Operating Procedures for Health and Disability Ethics Committees](#), para 54-59).

In both review pathways, the clock days went over. This appears to be primarily due to the changeover of online review system the HDECs were using partway through the reporting period, causing delays as a result of committee members, secretariat and researchers becoming more familiar with the system and able to respond in a timely manner.

Appendix 1: Details of applications reviewed¹

Applications reviewed by full committee

Review reference	Project title	Coordinating investigator	Review date received	Date of first review	Outcome of first review	Review status	Date of final outcome	Coordinating investigator organisation	Sponsor organisation
21/CEN/238	(duplicate) Feasibility of implementing Ballistic Strength Training to improve mobility outcomes in inpatients with Traumatic Brain Injury	Mrs Izel Gilfillan	16/08/2021	20/10/2021	Provisionally Approved	Approved	26/01/2022	ABI Rehabilitation,	Auckland District Health Board
21/NTA/154	(duplicate) HRcSCC	Mr Richard Martin	28/07/2021	14/12/2021	Approved	Approved	14/14/2021	North Shore Hospital, Waitemata District Health Board	New Zealand Clinical Research, Simbec-Orion
21/NTA/135	177Lu-DOTA-TLX591-CHO safety, biodistribution and dosimetry study (PROSTACT-Select)	Dr Remy Lim	22/07/2021	14/10/2021	Provisionally Approve	Approved	3/06/2022	Telix Pharmaceuticals NZ Ltd	Telix Pharmaceuticals NZ Ltd
21/NTA/132	272HV111: A Study to Evaluate Droxime Fumarate (BIB098) in Healthy Chinese and Caucasian Adults	Dr. Chris Wynne	22/07/2021	3/09/2021	Approved	Approved	3/09/2021 0:00	New Zealand Clinical Research Ltd.	IQVIA
2022 FULL 11715	A cohort study to evaluate the effect of ADF in adults with T2DM	Dr. Pedram Zavarreza	25/03/2022	11/03/2022	Provisionally Approve	Approved	12/04/2022	University of Canterbury	WeCare Health, University of Canterbury
2021 FULL 11105	A Long-term Follow-up Study of Sotatercept for PAH Treatment	Dr Henry Gallagher	29/10/2021	10/12/2021	Decline	Declined	10/12/2021	Waikato Hospital	Accelaron Pharma Inc., PPD Global Limited
2021 FULL 11059	A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma	Professor Anthony Wells	1/10/2021	9/11/2021	Decline	Declined	9/11/2021	Capital Eye Specialists	ONL Therapeutics, Inc., Syneos Health New Zealand Limited

¹ Data is directly reported from the online system. Any errors in spelling is reflected due to errors made by the applicant.

2021 FULL 11775	A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma (ONL1204-OAG-001)	Professor Anthony Wells	20/12/2021	9/12/2021	Provisionally Approve	Approved	28/01/2022	Capital Eye Specialists	ONL Therapeutics, Inc., Syneos Health New Zealand Limited
2022 FULL 11758	A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy	Dr Kannaiyan Rabindranath	25/02/2022	14/03/2022	Approved	Approved	14/03/2022	Waikato District Health Board	Eledon Pharmaceuticals, Inc., George Clinical Pty Ltd
21/NTA/166	A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL	Dr Peter Ganly	18/08/2021	20/09/2021	Approved	Approved	20/09/2021	Canterbury District Health Board	AstraZeneca Pty Ltd
2022 FULL 12515	A Phase I-III study evaluating the efficacy and safety of multiple therapies in cohorts of patients selected according to biomarker status, with stage III NSCLC	Dr Laird Cameron	9/06/2022	8/07/2022	Approved	Approved	8/07/2022	Auckland City Hospital	Roche Products (New Zealand) Limited
21/NTA/165	A study comparing R-192 and R-107 in healthy volunteers.	Dr Noelyn Hung	18/08/2021	12/10/2021	Approved	Approved	12/10/2021	Zenith Technology Corporation Limited	Douglas Pharmaceuticals Ltd
2021 FULL 11361	A Study of Midazolam Administered Intranasally Using the NasoSURF Device in Healthy Volunteers	Dr Alexandra Cole	22/11/2021	9/11/2021	Provisionally Approve	Approved	21/01/2022	New Zealand Clinical Research	AFT Pharmaceuticals
2022 FULL 12266	A Study of SZN-043 in Healthy Volunteers and Patients with Liver Cirrhosis	Principal Investigator Prof Ed Gane	6/04/2022	22/03/2022	Provisionally Approve	Approved	20/04/2022	New Zealand Clinical Research	Novotech Australia Pty Ltd
2022 FULL 12019	A study to assess differing doses of IMU-856 in healthy volunteers and patients with celiac disease.	Professor Richard Stubbs	25/03/2022	11/03/2022	Provisionally Approve	Approved	12/04/2022	P3 Research	Avance Clinical

2022 FULL 12069	A Study to Assess the Safety, Effects and How the Body Processes a New Drug, NT-0249 in Healthy Adults	Principal Investigator Dr Chris Wynne	24/01/2022	11/03/2022	Approved	Approved	11/03/2022	New Zealand Clinical Research	Novotech NZ Ltd
21/NTA/168	A Variable Length Efficacy and Safety Study to Assess an Inhaled, Fixed-dose,	Dr Dean Quinn	19/08/2021	12/10/2021	Provisionally Approve	Approved	18/11/2021	P3 Research	AstraZeneca Pty Ltd
2022 FULL 11110	ACTION3	Dr Tze Liang Goh	17/01/2022	9/11/2021	Provisionally Approve	Approved	11/02/2022	Auckland District Health Board	Dimerix Bioscience Pty Ltd, IQVIA RDS Pty. Ltd
2022 FULL 12863	Advanced MR Imaging at MĀ• tai	Dr Daniel Cornfeld	30/06/2022	28/07/2022	Decline	Declined	28/07/2022	Matai Medical Research Institute	Matai Medical Research Institute
2021 FULL 11431	ALXN1840-WD-204: A Study to Assess ALXN1840 in Participant's with Wilson Disease	Prof. Edward Gane	3/11/2021	10/12/2021	Approved	Approved	10/12/2021	New Zealand Clinical Research Ltd	Alexion Pharmaceuticals, Inc., Syneos Health New Zealand Ltd.
2021 FULL 11513	Assessment of a New Automated Insulin Delivery System	Dr Martin de Bock	17/12/2021	10/12/2021	Provisionally Approve	Approved	28/01/2022	University of Otago	University of Otago
2022 FULL 12545	BP43963: A Study of RO7247669 in Participants with Melanoma	Dr Rajiv Kumar	13/05/2022	3/05/2022	Provisionally Approve	Approved	30/05/2022	New Zealand Clinical Research	Roche Products (New Zealand) Limited
2021 FULL 11749	CN42097_A Clinical Trial to Examine if an Injection of Ocrelizumab Under the Skin is a Safe and Effective Alternative Way of Treating Patients with Multiple Sclerosis (MS)	Dr Jennifer Pereira	18/11/2021	9/12/2021	Approved	Approved	9/12/2021	Optimal Clinical Trials	Roche Products (New Zealand) Limited
21/NTA/130	Comparison of two rosuvastatin formulations.	Dr Noelyn Hung	21/07/2021	3/09/2021	Approved	Approved	3/09/2021	Zenith Technology Corporation Limited	Aspen Australia
2022 FULL 11152	Cytisine and e-cigarettes study with supportive text-messaging	Associate Professor Natalie Walker	18/03/2022	9/12/2021	Provisionally Approve	Approved	24/03/2022	University of Auckland, The University of Auckland	University of Auckland, The University of Auckland
2021 FULL 11184	Delta-Max	Professor Jamie Sleight	27/09/2021	9/11/2021	Decline	Declined	9/11/2021	University of Auckland	University of Auckland
2021 FULL 11916	Delta-Max Trial	Professor Jamie Sleight	10/12/2021	11/03/2022	Approved	Approved	11/03/2022	University of Auckland	University of Auckland

2022 FULL 11051	Dexmedetomidine verses standard of care (SOC) in the management of agitation in palliative care	Dr Lana Ferguson	21/01/2022	9/11/2021	Provisionally Approve	Approved	17/02/2022	Waikato DHB	Waikato DHB
21/NTA/163	Digital buddy for preparation of IV insertion	Dr Jo Hegarty	17/08/2021	12/10/2021	Provisionally Approve	Approved	23/03/2022	Starship Hospital	University of Otago
21/NTA/136	DoxAPrem Study	Dr Christopher McKinlay	23/07/2021	3/09/2021	Approved	Approved	3/09/2021	Liggins Institute	Massey University
2022 EXP 11562	Effect of Exercise on Sleep Quality in Children with Autism Spectrum Disorder/Takiwā tanga: A Pilot Study	Dr Gloria Dainty	17/02/2022	10/12/2021	Provisionally Approve	Approved	29/03/2022	Southern District Health Board	Southern District Health Board
2022 EXP 12593	Experiences of injuries to the head and neck following domestic violence	Professor/Dr Alice Theadom	9/06/2022	27/05/2022	Provisionally Approve	Approved	13/07/2022	Auckland University of Technology	Auckland University of Technology
2022 EXP 12086	Experiences of injuries to the head as a consequence of domestic violence	Professor/Dr Alice Theadom	25/02/2022	22/03/2022	Decline	Declined	22/03/2022	Auckland University of Technology	Auckland University of Technology
2022 FULL 11767	Finding a better nasal anaesthetic	Dr. Samuel Hale	7/06/2022	22/03/2022	Provisionally Approve	Approved	13/07/2022	University of Auckland	University of Auckland
21/NTA/167	Flu Lab - Community Respiratory Virus Surveillance in Pre-school Children	A/P Catherine Byrnes	19/08/2021	12/10/2021	Provisionally Approve	Approved	1/12/2021	Middlemore Clinical Trials	University of Canterbury
21/NTA/142	Genetic markers in ovarian cancers in New Zealand (NOVel)	Doctor Bryony Simcock	23/07/2021	3/09/2021	Decline	Declined	3/09/2021	University of Otago	University of Otago
2021 FULL 11729	GO43643: An Open-Label Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin in Participant with Aggressive B-Cell Non Hodgkin's Lymphoma	Dr Samar Issa	16/11/2021	9/12/2021	Approved	Approved	9/12/2021	Middlemore Clinical Trials	Roche Products (New Zealand) Limited
2021 FULL 11283	HB0034-01: A Study to Evaluate HB0034 in Healthy Adult Participants	Doctor Christian Schwabe	29/09/2021	9/11/2021	Approved	Approved	9/11/2021	New Zealand Clinical Research Ltd	Shanghai Huaota Biopharmaceutical Co., Ltd, Syneos

									Health New Zealand Ltd.
21/NTA/144	Impact of parental brain injury on their children's quality of life	Mrs Audrey McKinlay	27/07/2021	Not approved	Decline	Declined	3/09/2021	University of Canterbury	
2022 FULL 11612	Intraosseous Regional Administration of Diclofenac (IRAD) in Primary TKA Study	Mr Simon Young	25/01/2022	11/03/2022	Approved	Approved	11/03/2022	Southern Cross Hospital	Southern Cross Hospital
2022 FULL 11411	ION-682884-CS13/Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884	Prof Edward (Ed) Gane	6/05/2022	27/05/2022	Approved	Approved	27/05/2022	Auckland City Hospital	Ionis Pharmaceuticals Inc, Pharmaceutical Research Associates New Zealand Limited
21/NTA/152	ITL-2002-CL-001 (Resubmission): A Study to Evaluate NTLA-2002 in Patients with Hereditary Angioedema (HAE)	Dr. Hilary Longhurst	5/08/2021	5/10/2021	Approved	Approved	5/10/2021	Auckland Clinical Studies	ABI Rehabilitation
21/NTA/161	KVD824-201	Dr Anthony Jordan	16/08/2021	13/10/2021	Provisionally Approve	Approved	13/12/2021	Auckland City Hospital	CCDHB
2022 FULL 11760	M20-178 (TRANSFORM-2) Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Best Available Therapy	Dr James Liang	20/01/2022	11/03/2022	Approved	Approved	11/03/2022	Middlemore Clinical Trials	AbbVie Pty Ltd
2021 FULL 11329	M20-178: Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Best Available Therapy (TRANSFORM 2)	Dr James Liang	29/09/2021	9/11/2021	Decline	Declined	9/11/2021	Middlemore Clinical Trials	AbbVie Pty Ltd
2021 EXP 11861	Management of the Absolutely Ligamentous Lisfranc injury €" Early fusion versus fixation Treatment: the mini-MALLET trial; a pilot randomised controlled trial	Dr Matthew D'Arcy	6/12/2021	11/01/2022	Approved	Approved	11/01/2022	Canterbury District Health Board	Canterbury District Health Board
2022 FULL 12382	Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients with Malignant Tumours	Dr Laird Cameron	9/06/2022	8/07/2022	Approved	Approved	8/07/2022	Auckland City Hospital	Roche Products (New Zealand) Limited

21/NTA/169	Micronutrients and emotion dysregulation and irritability in children between 5 and 10 years of age	Miss Nurina Maria Katta	19/08/2021	12/10/2021	Provisionally Approve	Approved	29/11/2021	University of Canterbury	Pharmaceutical Solutions Limited, PharmaSols
2021 FULL 11197	Mini S Feasibility Study	Dr Andrew Holden	22/11/2021	9/11/2021	Provisionally Approve	Approved	28/01/2022	Auckland District Health Board	Shockwave Medical, Inc
2022 FULL 11317	Novel white crowns for drill-free treatment of dental caries in NZ children	Dr Joanne Jung Eun Choi	28/02/2022	22/03/2022	Decline	Declined	22/03/2022	University of Otago	University of Otago
2022 FULL 12039	Nutrition status in childhood cancer	Dr Amy Lovell	8/04/2022	11/03/2022	Provisionally Approve	Approved	17/05/2022	The University of Auckland	The University of Auckland
2022 FULL 12267	Open-label long-term trial of efgartigimod PH20 SC for the treatment of Primary Immune Thrombocytopenia in adults (ARGX-113-2005)	Dr Rajeev Rajagopal	26/05/2022	3/05/2022	Provisionally Approve	Approved	14/06/2022	Middlemore Clinical Trials	ICON Clinical Research (New Zealand) Ltd
2022 FULL 11479	Oxygen Wound Therapy Feasibility Study	Mrs Jo Krysa	7/06/2022	3/05/2022	Provisionally Approve	Approved	16/06/2022	Southern DHB	Fisher & Paykel Healthcare
2021 EXP 11418	Physical activity and health: The effect of GoldFit YMCA participation on the brain, breathing and blood pressure regulation	Miss Thalia Babbage	17/11/2021	9/12/2021	Approved	Approved	9/12/2021	University of Auckland	University of Auckland
21/NTA/170	Psilocybin-assisted therapy for depression	Dr Cameron Lacey	19/08/2021	26/11/2021	Provisionally Approve	Approved	11/02/2022	University of Otago	University of Auckland
21/NTA/164	PUMAS Study	Dr Sean Coffey	17/08/2021	12/10/2021	Provisionally Approve	Approved	9/12/2021	University of Otago	IQVIA
2022 FULL 12294	Reboot KIDS - Healthy Eating for childhood cancer survivors	Dr Amy Lovell	8/04/2022	22/03/2022	Provisionally Approve	Approved	16/05/2022	The University of Auckland	The University of Auckland
21/NTA/162	Recombinant human alkaline phosphatase SA-AKI survival trial (REVIVAL)	Professor Paul Young	17/08/2021	12/10/2021	Provisionally Approve	Approved	2/12/2021	CCDHB	AM Pharma
2022 FULL 12504	Rectal concentrations of thioguanine in inflammatory bowel disease 2	Professor Murray Barclay	5/05/2022	27/05/2022	Approved	Approved	27/05/2022	Barclay Gastroenterology Ltd	Barclay Gastroenterology Ltd,

21/NTA/159	Responsibilising Opioid Users: OST as €Biopower€™?	Mr Oliver Birch	20/08/2021	Not approved	Decline	Declined	12/10/2021	The University of Auckland	
2022 FULL 11818	RESTORE-MI Trial	Professor Harvey Douglas White	9/05/2022	11/03/2022	Provisionally Approve	Approved	30/05/2022	Auckland District Health Board	The University of Sydney
21/NTA/138	Short-term exposure to biodiversity and health	Dr Collin Brooks	26/07/2021	6/12/2021	Approved	Approved	6/12/2021	Massey University	North Shore Hospital
21/NTA/133	Skyscraper03: GO41854 Tiragolumab + Tecentriq vs Durvalumab in Unresectable Stage III NSCLC	Dr Laird Cameron	22/07/2021	27/10/2021	Approved	Approved	27/10/2021	Auckland City Hospital	Roche Products New Zealand Ltd.
21/NTA/131	SNAP	Dr Genevieve Walls	22/07/2021	3/11/2021	Approved	Approved	3/11/2021	Middlemore Clinical Trials	Middlemore Clinical Trials
2022 FULL 11325	SONIC - Study Of Neck Injuries In Children	Professor Stuart Dalziel	5/05/2022	27/05/2022	Approved	Approved	27/05/2022	Auckland District Health board	Auckland District Health board
21/NTA/160	SUMMIT MAX	Dr Ben McGuinness	20/08/2021	12/10/2021	Provisionally Approve	Approved	18/11/2021	Auckland District Health Board	The University of Auckland
2022 EXP 12176	Text based support following a suicide attempt	Dr Lillian Ng	25/02/2022	22/03/2022	Decline	Declined	22/03/2022	The University of Auckland	The University of Auckland
2022 FULL 12162	The CI-DEX Study	Associate Professor Holly Teagle	6/05/2022	27/05/2022	Decline	Declined	27/05/2022	Cochlear Limited	Cochlear Limited
2022 EXP 12321	The Hawkes Bay Sprains and Strains Surveillance, Management and Prevention Programme.	Associate Professor Ian Laird	9/05/2022	22/04/2022	Provisionally Approve	Approved	17/05/2022	Massey University	Massey University
2022 FULL 11225	The Orthopaedic Device Infection Network (ODIN)	Mr Simon Young	1/03/2022	10/12/2021	Provisionally Approve	Approved	30/05/2022	Waitemata District Health Board	Waitemata District Health Board
2022 FULL 11962	TRITON glaucoma or ocular hypertension (Resubmission)	Professor Anthony Wells	7/04/2022	22/03/2022	Provisionally Approve	Approved	11/05/2022	Capital Eye Specialists	Allergan New Zealand Limited
2021 FULL 11120	Tuning in to Teens in Aotearoa New Zealand	Ms Zara Mansoor	5/10/2021	9/11/2021	Decline	Declined	9/11/2021	University of Otago	University of Otago
2021 FULL 11218	Walk a mile in their shoes - Developing a virtual reality experience of FASD	Dr Joanna Ting Wai Chu	2/11/2021	10/12/2021	Decline	Declined	10/12/2021	University of Auckland	University of Auckland
2021 FULL 11284	YH003004: A Study to Evaluate YH003 in Combination with Toripalimab in Patients	Doctor Rajiv Kumar	28/09/2021	9/11/2021	Approved	Approved	9/11/2021	New Zealand Clinical Research	IQVIA

	with Unresectable/Metastatic Melanoma and Pancreatic Ductal Adenocarcinoma (PDAC)								
--	---	--	--	--	--	--	--	--	--